Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
Status: | Recruiting |
---|---|
Conditions: | Dermatology, Dermatology, Hair Loss |
Therapuetic Areas: | Dermatology / Plastic Surgery |
Healthy: | No |
Age Range: | 18 - 49 |
Updated: | 4/21/2016 |
Start Date: | March 2016 |
End Date: | April 2017 |
Contact: | Clincial Trials Registry Team |
Email: | IR-CTRegistration@Allergan.com |
Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men
This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients
with androgenetic alopecia (AGA).
with androgenetic alopecia (AGA).
Inclusion Criteria:
- Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss
for at least 1 year
Exclusion Criteria:
- History of Paget's disease, osteoporosis, or bone malignancy
- History of bone fracture within the previous 12 months, except for metatarsal,
metacarpal, or skull fractures
- Patient is currently undergoing radiation therapy or anticipates undergoing radiation
therapy at any time during the study
- Drug or alcohol abuse within 12 months
- HIV positive
- Received hair transplants or had scalp reductions
- Use of hair weaves, hair extensions or wigs within 3 months
- Application of topical medications, minoxidil or nonsteroidal anti-inflammatory drugs
(NSAIDs) to scalp within 4 weeks
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials